PRMT2
Basic information
Region (hg38): 21:46635595-46665685
Previous symbols: [ "HRMT1L1" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PRMT2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 3 | |||||
missense | 13 | 17 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 0 | |||||
Total | 0 | 0 | 13 | 5 | 2 |
Variants in PRMT2
This is a list of pathogenic ClinVar variants found in the PRMT2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
21-46643538-G-A | not specified | Uncertain significance (Nov 03, 2022) | ||
21-46643548-C-T | not specified | Likely benign (Nov 21, 2024) | ||
21-46643557-G-T | not specified | Uncertain significance (Sep 22, 2023) | ||
21-46643596-A-T | not specified | Uncertain significance (Jun 30, 2023) | ||
21-46643598-T-C | not specified | Uncertain significance (Oct 12, 2024) | ||
21-46643619-G-A | not specified | Uncertain significance (Sep 20, 2023) | ||
21-46644328-A-C | not specified | Uncertain significance (Feb 22, 2023) | ||
21-46644375-C-T | not specified | Uncertain significance (Aug 20, 2024) | ||
21-46644376-G-A | not specified | Uncertain significance (Mar 20, 2024) | ||
21-46644400-C-T | not specified | Uncertain significance (Jun 02, 2024) | ||
21-46644470-C-T | Likely benign (Feb 01, 2023) | |||
21-46644477-T-A | not specified | Uncertain significance (Jul 31, 2024) | ||
21-46644495-C-T | Benign (May 21, 2018) | |||
21-46648497-A-G | not specified | Uncertain significance (Nov 15, 2021) | ||
21-46648534-C-T | not specified | Uncertain significance (Dec 28, 2022) | ||
21-46649582-C-T | not specified | Uncertain significance (Jul 26, 2024) | ||
21-46649679-T-C | Likely benign (Aug 02, 2018) | |||
21-46649691-C-T | Benign (Jul 02, 2018) | |||
21-46649698-G-A | not specified | Uncertain significance (Dec 17, 2021) | ||
21-46649728-A-C | not specified | Uncertain significance (May 14, 2024) | ||
21-46658821-T-C | not specified | Likely benign (Oct 26, 2022) | ||
21-46658854-A-T | not specified | Uncertain significance (Dec 06, 2024) | ||
21-46658866-G-A | not specified | Likely benign (May 31, 2022) | ||
21-46658880-T-C | not specified | Uncertain significance (Mar 30, 2024) | ||
21-46658913-G-A | not specified | Uncertain significance (Dec 06, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PRMT2 | protein_coding | protein_coding | ENST00000397637 | 10 | 29958 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00161 | 0.997 | 125724 | 0 | 24 | 125748 | 0.0000954 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.79 | 174 | 254 | 0.684 | 0.0000151 | 2834 |
Missense in Polyphen | 70 | 113.48 | 0.61683 | 1282 | ||
Synonymous | -0.0223 | 111 | 111 | 1.00 | 0.00000823 | 803 |
Loss of Function | 2.84 | 9 | 24.1 | 0.374 | 0.00000117 | 266 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000159 | 0.000158 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000471 | 0.0000462 |
European (Non-Finnish) | 0.000115 | 0.000114 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000132 | 0.000131 |
Other | 0.000174 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Arginine methyltransferase that methylates the guanidino nitrogens of arginyl residues in proteins such as STAT3, FBL, histone H4. Acts as a coactivator (with NCOA2) of the androgen receptor (AR)-mediated transactivation. Acts as a coactivator (with estrogen) of estrogen receptor (ER)-mediated transactivation. Enhances PGR, PPARG, RARA-mediated transactivation. May inhibit NF-kappa-B transcription and promote apoptosis. Represses E2F1 transcriptional activity (in a RB1- dependent manner). May be involved in growth regulation. {ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17587566, ECO:0000269|PubMed:19405910}.;
- Pathway
- Retinoblastoma (RB) in Cancer;mRNA Processing;AndrogenReceptor
(Consensus)
Recessive Scores
- pRec
- 0.235
Intolerance Scores
- loftool
- 0.750
- rvis_EVS
- -0.02
- rvis_percentile_EVS
- 52.09
Haploinsufficiency Scores
- pHI
- 0.173
- hipred
- Y
- hipred_score
- 0.775
- ghis
- 0.541
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.987
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Prmt2
- Phenotype
- cellular phenotype; homeostasis/metabolism phenotype; skeleton phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan);
Gene ontology
- Biological process
- regulation of transcription, DNA-templated;protein methylation;signal transduction;histone methylation;peptidyl-arginine methylation, to asymmetrical-dimethyl arginine;negative regulation of NF-kappaB transcription factor activity;histone arginine methylation;positive regulation of apoptotic process;negative regulation of transcription, DNA-templated;positive regulation of transcription, DNA-templated;developmental cell growth;regulation of androgen receptor signaling pathway;negative regulation of G1/S transition of mitotic cell cycle
- Cellular component
- nucleus;nucleoplasm;nucleolus;cytoplasm;cytosol
- Molecular function
- transcription coactivator activity;protein binding;histone-arginine N-methyltransferase activity;protein-arginine N-methyltransferase activity;estrogen receptor binding;progesterone receptor binding;protein-arginine omega-N asymmetric methyltransferase activity;histone methyltransferase activity;protein homodimerization activity;retinoic acid receptor binding;peroxisome proliferator activated receptor binding;protein-containing complex binding;thyroid hormone receptor binding;androgen receptor binding